Navigation Links
Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
Date:2/4/2008

Deal follows positive phase I data from novel product candidate AM103 for

the oral treatment of respiratory disease

SAN DIEGO, Feb. 4 /PRNewswire/ -- Amira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein ) inhibitors for the treatment of respiratory and cardiovascular disease.

Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira's FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments. In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.

Initial development activities will focus on candidate compound AM103, for the treatment of asthma. Positive data, from a phase I study completed in November 2007, show AM103 has the potential as a once-daily, oral, non-steroidal asthma treatment. In this study the compound was also well-tolerated.

Peppi Prasit, Chief Scientific Officer and Co-Founder Amira said: "To have identified such a positive drug candidate and progressed to the completion of phase I clinical trials just two years after the company was founded is a tremendous achievement for the team at Amira. We are delighted that GlaxoSmithKline will be taking this asset into full development. With their experience and expertise in this area we hope that AM103 will become the first FLAP inhibitor available to patients worldwide to treat symptoms of asthma and possibly other inflammatory diseases."

"This is a momentous day in the young life of Amira," said Bob Baltera, Chief Executive Officer, Amira. "This deal valid
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Amira Pharmaceuticals Appoints First Vice President of Development
2. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
5. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
6. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
7. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
8. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
9. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The 2013 edition of ... chemical listings, appellate decisions, litigation and settlement trends, ... compliance with California's Proposition 65. , The Handbook ... regulations, history and trends impacting California's Proposition 65. ... of the series which adds approximately 200 pages ...
(Date:7/31/2014)... On October 10, at the Palmer ... Applied Research Foundation, in collaboration with the University ... mesothelioma conference geared to patients and ... to mesothelioma and presented by local and regional ... include imaging, genetics, first-line therapies, surgery, chemotherapy, radiation ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Nashville, TN (PRWEB) July 31, 2014 ... TN was one of the first surgeons in the United ... the iStent, the smallest medical device ever approved ... the first surgeons to recognize the benefits of using a ... patients with glaucoma. Dr. Shofner and his colleagues now recognize ...
(Date:7/31/2014)... 2014 The vineyards are lush, and the ... And, to celebrate, folks are gearing up for the annual ... and 7, 2014 along the Leelanau Peninsula Wine Trail ... or run through the vineyards start-ing at 9:00 a.m. on ... unique course between rows of grapevines offers an experience like ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2
... , TUESDAY, Feb. 21 (HealthDay News) -- Insulin production may ... according to a new study. The findings add to ... the onset of the disease is longer than previously believed, ... thought that beta cell function completely ceased in patients with ...
... recession was the longest and most severe since World War ... at the slowest rate in over 50 years, suggesting that ... that these cut backs were not limited to Americans who ... at the University of North Carolina at Chapel Hill School ...
... , New Rochelle, NY, February 21, 2012Faith-based advocacy has ... obesity, but evidence is needed to support this assertion ... policy can contribute to promoting permanent lifestyle changes. This ... journal Childhood Obesity celebrating the second anniversary ...
... News) -- Researchers who traced the evolution of a ... livestock to humans say their findings highlight the dangers ... The international team of scientists studied methicillin-resistant Staphylococcus ... livestock-associated MRSA, which most often infects people with direct ...
... By reformulating the common cancer drug imatinib (Gleevec), researchers ... step toward improving the effectiveness of chronic pain management ... Texas MD Anderson Cancer Center. Narcotics such as ... time, tolerance to the pain-relieving effects of these drugs ...
... rescues malignant cells from destruction by extending the protective caps ... triggers resistance pathways that allow cancer to survive and spread, ... . "Telomerase is overexpressed in many advanced cancers, but ... understand what it does and how it does it," said ...
Cached Medicine News:Health News:Type 1 Diabetes May Develop More Slowly Than Thought 2Health News:Recession and high co-pays tied to fewer colonoscopy screenings among people with health insurance 2Health News:Childhood obesity -- can faith-based organizations make a difference? 2Health News:Pig-to-Human 'Superbug' May Be Due to Animal Antibiotics 2Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 3Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 4
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... STXS ) announced today the appointment of ... (EMEA) to lead the Company,s EMEA operations and sales ... utilization of its Niobe® Remote Magnetic Navigation System and ... P. Kaminski, President and CEO of Stereotaxis. ...
... Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial ... For the third quarter of 2010, the Company reported net income ... loss of $8.2 million, or $0.21 per share, for the same ... the Company reported a net loss of $10.5 million, or $0.20 ...
Cached Medicine Technology:Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 2Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 3Neurocrine Biosciences Reports Third Quarter 2010 Results 2Neurocrine Biosciences Reports Third Quarter 2010 Results 3Neurocrine Biosciences Reports Third Quarter 2010 Results 4Neurocrine Biosciences Reports Third Quarter 2010 Results 5Neurocrine Biosciences Reports Third Quarter 2010 Results 6Neurocrine Biosciences Reports Third Quarter 2010 Results 7Neurocrine Biosciences Reports Third Quarter 2010 Results 8
Inquire...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: